for the Period Ended 31 December 2023
Directors report | |
Profit and loss | |
Balance sheet | |
Additional notes | |
Balance sheet notes |
Directors' report period ended
The directors present their report with the financial statements of the company for the period ended 31 December 2023
Principal activities of the company
Additional information
In Quarter 4 of 2024, it is planned that the trade, assets and liabilities of the company will be purchased by Werfen Ltd, a commonly owned sister company, with the expected consideration payable being based upon the book value of the net assets at the time of the transaction. This will allow the business to benefit from not only the support that can be provided by Werfen Ltd but also the economies of scale that can be leveraged. Following the sale of the business, it is the directors' intention that any remaining assets (such as the consideration received for the sale of trade and net assets) would be used to satisfy any final obligations before the residual amount is distributed to shareholders. Ultimately, the directors expect that the legal entity will be entered into a liquidation process at some stage during 2025. For these reasons, the financial statements have been drawn up on a basis other than going concern.
Directors
The directors shown below have held office during the whole of the period from
1 January 2023
to
31 December 2023
The director shown below has held office during the period of
1 January 2023
to
2 November 2023
The director shown below has held office during the period of
1 January 2023
to
10 July 2023
The directors shown below have held office during the period of
2 November 2023
to
31 December 2023
Secretary
The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006
This report was approved by the board of directors on
And signed on behalf of the board by:
Name:
Status: Director
for the Period Ended
2023 | 2022 | |
---|---|---|
|
£ |
£ |
Turnover: |
|
|
Cost of sales: |
(
|
(
|
Gross profit(or loss): |
|
|
Distribution costs: |
(
|
(
|
Administrative expenses: |
(
|
(
|
Operating profit(or loss): |
|
|
Interest receivable and similar income: |
|
|
Interest payable and similar charges: |
(
|
(
|
Profit(or loss) before tax: |
|
|
Tax: |
(
|
(
|
Profit(or loss) for the financial year: |
|
|
As at
Notes | 2023 | 2022 | |
---|---|---|---|
|
£ |
£ |
|
Fixed assets | |||
Intangible assets: | 3 |
|
|
Tangible assets: | 4 |
|
|
Investments: | 5 |
|
|
Total fixed assets: |
|
|
|
Current assets | |||
Stocks: | 6 |
|
|
Debtors: | 7 |
|
|
Cash at bank and in hand: |
|
|
|
Total current assets: |
|
|
|
Creditors: amounts falling due within one year: | 8 |
(
|
(
|
Net current assets (liabilities): |
|
|
|
Total assets less current liabilities: |
|
|
|
Provision for liabilities: |
(
|
(
|
|
Total net assets (liabilities): |
|
|
|
Capital and reserves | |||
Called up share capital: |
|
|
|
Share premium account: |
|
|
|
Profit and loss account: |
|
|
|
Total Shareholders' funds: |
|
|
The notes form part of these financial statements
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 31 December 2023
Basis of measurement and preparation
Turnover policy
Tangible fixed assets depreciation policy
Intangible fixed assets amortisation policy
for the Period Ended 31 December 2023
2023 | 2022 | |
---|---|---|
Average number of employees during the period |
|
|
for the Period Ended 31 December 2023
Goodwill | Other | Total | |
---|---|---|---|
Cost | £ | £ | £ |
At 1 January 2023 |
|
|
|
Additions | |||
Disposals | |||
Revaluations | |||
Transfers | |||
At 31 December 2023 |
|
|
|
Amortisation | |||
At 1 January 2023 |
|
|
|
Charge for year |
|
|
|
On disposals | |||
Other adjustments | |||
At 31 December 2023 |
|
|
|
Net book value | |||
At 31 December 2023 |
|
|
|
At 31 December 2022 |
|
|
for the Period Ended 31 December 2023
Land & buildings | Plant & machinery | Fixtures & fittings | Office equipment | Motor vehicles | Total | |
---|---|---|---|---|---|---|
Cost | £ | £ | £ | £ | £ | £ |
At 1 January 2023 |
|
|
|
|||
Additions |
|
|
|
|||
Disposals |
(
|
(
|
(
|
|||
Revaluations | ||||||
Transfers | ||||||
At 31 December 2023 |
|
|
|
|||
Depreciation | ||||||
At 1 January 2023 |
|
|
|
|||
Charge for year |
|
|
|
|||
On disposals |
(
|
(
|
(
|
|||
Other adjustments | ||||||
At 31 December 2023 |
|
|
|
|||
Net book value | ||||||
At 31 December 2023 |
|
|
|
|||
At 31 December 2022 |
|
|
|
for the Period Ended 31 December 2023
Instruments are held to generate rental income (note 4). Rental income from operating leases is recognised on a straight-line basis over the lease term. The registered office of both Immucor Limited and Quest Biomedical Limited is 2 Cranbrook Way, Solihull Business Park, Solihull, West Midlands B90 4GT. Both Immucor Ltd and Quest Biomedical Limited remained dormant throughout the year ending 31 December 2023 (2022: Dormant). Immucor Ltd and Quest Biomedical Limited have assets with a value of £2 (2022: £2) each represented by debtors.
for the Period Ended 31 December 2023
2023 | 2022 | |
---|---|---|
£ | £ | |
Stocks |
|
|
Total |
|
|
for the Period Ended 31 December 2023
2023 | 2022 | |
---|---|---|
£ | £ | |
Trade debtors |
|
|
Prepayments and accrued income |
|
|
Other debtors |
|
|
Total |
|
|
for the Period Ended 31 December 2023
2023 | 2022 | |
---|---|---|
£ | £ | |
Amounts due under finance leases and hire purchase contracts |
|
|
Trade creditors |
|
|
Taxation and social security |
|
|
Accruals and deferred income |
|
|
Other creditors |
|
|
Total |
|
|